showed that increased expression of phosphorylated ERBB3 is a key resistance mechanism in FGFR3-dependent bladder cancer and that dual targeting of FGFR3 and ERBB3 delayed the reactivation of pERBB3 and enhanced FGFR inhibitor efficacy (74). Here, ERBB3 is linked to urinary bladder cancer.